NDANASALSPRAY, METERED
Approved
Jan 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
NASCOBAL (cyanocobalamin) by Accord Biopharma is 12 can be converted to coenzyme b 12 in tissues, and as such is essential for conversion of methylmalonate to succinate and synthesis of methionine from homocysteine, a reaction which also requires folate. First approved in 2005.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NASCOBAL is a nasal spray formulation of cyanocobalamin (vitamin B12) approved in 2005 for treating vitamin B12 deficiency. It works by converting to coenzyme B12, essential for methylmalonate-to-succinate conversion, methionine synthesis, and maintaining enzyme cofactor function. The drug is indicated for patients who cannot absorb B12 via oral or intramuscular routes.
$0.008BPart D
LOE ApproachingProduct is in decline phase with minimal Part D volume (12 claims in 2023), suggesting a small and shrinking commercial footprint requiring defensive rather than growth-oriented strategies.
Mechanism of Action
12 can be converted to coenzyme B 12 in tissues, and as such is essential for conversion of methylmalonate to succinate and synthesis of methionine from homocysteine, a reaction which also requires folate. In the absence of coenzyme B 12 , tetrahydrofolate cannot be regenerated from its inactive…
Pharmacologic Class:
Vitamin B12
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Effect of Methylcobalamin and Cyanocobalamin Consumption on Vitamin B12 Nutritional Status
Started Sep 2023
54 enrolled
Vitamin B12 Nutritional Deficiency
Characterization of Cyanocobalamin in Healthy Voluteers After Intranasal and Intramuscual Administration
Started Feb 2011
16 enrolled
Focus: Bioavailability
Worked on NASCOBAL at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.